

=> s nicotinic receptor#

5894 NICOTINIC  
40504 RECEPTOR#  
L1 134 NICOTINIC RECEPTOR#  
                 (NICOTINIC (W) RECEPTOR#)

=> s alpha-7 (4A) 11

279691 ALPHA  
2124556 7  
1375 ALPHA-7  
✓ (ALPHA(W) 7)  
L2 4 ALPHA-7 (4A) L1

=> d 12 1-4

1. 5,929,034, Jul. 27, 1999, Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release; J. Michael McIntosh, et al., 514/13 [IMAGE AVAILABLE]

2. 5,922,679, Jul. 13, 1999, Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release; J. Michael McIntosh, et al., 514/13 [IMAGE AVAILABLE]

3. 5,780,433, Jul. 14, 1998, Use of .alpha.-conotoxin MII to treat disorders resulting from nicotine stimulated dopamine release; J. Michael McIntosh, et al., 514/13, 813 [IMAGE AVAILABLE]

4. 5,733,912, Mar. 31, 1998, 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission; James T. Wasicak, et al., 514/253, 256, 314, 339, 378, 406; 544/238, 242, 334, 336; 546/152, 276.7; 548/235, 364.7 [IMAGE AVAILABLE]

=> d 3-4 hit

US PAT NO: 5,780,433 [IMAGE AVAILABLE]

L2: 3 of 4

**DETDESC:**

DETD (37)

.alpha.-Conotoxin MII is selective for the .alpha.3.beta.2 subtype of nicotinic receptor. Structurally-related .alpha.-conotoxins which target

non-.alpha.3.beta.2 nicotinic subtypes were tested to determine whether they blocked nicotine-stimulated dopamine release (see Table I). .alpha.-Conotoxin MI, specific for the muscle subtype of nicotinic receptor and .alpha.-conotoxin IMI, specific for the **.alpha.7** subtype of **nicotinic receptor** (Johnson et al., 1995) had no effect on release (FIG. 2).

US PAT NO: 5,733,912 [IMAGE AVAILABLE]

L2: 4 of 4

CLAIMS:

CLMS (5)

5. A compound according to claim 1 wherein the compound has binding affinity at both an alpha-4-beta-2 **nicotinic receptor** subtype and an **alpha-7 nicotinic receptor** subtype.